Simcere Pharmaceutical Group Limited (FRA:S2P)

Market Cap	2.83B +20.0%
Revenue (ttm)	941.44M +16.5%
Net Income	163.66M +86.2%
EPS	0.07 +87.9%
Shares Out	n/a
PE Ratio	17.26
Forward PE	14.21
Dividend	0.02 (1.81%)
Ex-Dividend Date	Jun 18, 2025

Volume	n/a
Open	1.050
Previous Close	1.070
Day's Range	1.050 - 1.050
52-Week Range	1.050 - 1.600
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 4, 2026

About FRA:S2P

Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. It develops Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Leruiping, a fully human monoclonal antibody targeting IL-4Rα; Zemprocitinib a highly selective JAK1 inhibitor; and Xianlinda, an inhibitor for influenza polymerase acidic protein that has completed Phase 3 clini...

• Industry: Pharmaceutical Preparations
• Founded: 1995
• Employees: 7,038
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: S2P

Financial Performance

In 2025, FRA:S2P's revenue was 7.73 billion, an increase of 16.52% compared to the previous year's 6.64 billion. Earnings were 1.34 billion, an increase of 86.15%.

Financial numbers in CNY